• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.40 +0.85 (+2.10%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 612,346
Open 40.93
Bid (Size) 40.50 (3,000)
Ask (Size) 43.00 (200)
Prev. Close 40.55
Today's Range 40.05 - 41.82
52wk Range 15.86 - 50.81
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup ↗
September 05, 2026
Via Chartmill
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire

Performance

52-Week Range 18.5% below 52-week high
41.40
15.8652W Low 50.8152W High
1 Week 1.0% below 1-week high
39.751W Low 41.821W High

UroGen Pharma Ltd. - Ordinary Shares (URGN) traded between $15.86 and $50.81 over the past 52 weeks and last traded at $41.40, 18.5% below its 52-week high. Over the past week it ranged between $39.75 and $41.82.

Past 12 Months
+1.2%
-6.8%
+10.7%
+122.5%
+82.3%
+142.5%
1W +$0.50
1M -$3.02
3M +$3.99
6M +$22.79
YTD +$18.69
1Y +$24.33

URGN was +142.5% over the past year, +122.5% over six months, +82.3% year to date, +1.2% in the last week.

12 Months vs Market
URGN
+142.5%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months URGN returned +142.5% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.74× 3-mo avg
Today 612,346 3-mo avg 829.0K
1W
737.4K
1M
742.7K
3M
829.0K
6M
818.5K
YTD
803.8K
1Y
863.0K

URGN most recently traded 612,346 shares against a 3-month average daily volume of 829.0K.

More News

Read More
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
September 02, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
August 20, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
August 17, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗
July 09, 2026
Via Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗
June 08, 2026
Via Chartmill
News headline image
UroGen (URGN) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Urogen Pharma Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
News headline image
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 05, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
July 29, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗
July 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
July 08, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗
June 30, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗
June 14, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 02, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 01, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
May 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
May 23, 2026
Via The Motley Fool
News headline image
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q1 2026 Earnings Transcript ↗
May 07, 2026
Via The Motley Fool
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
May 07, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 41.40
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 10/02/26 04:00 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 1.50B
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap